Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Kokelj F., Plozzer C., Trevisan G.
Università degli Studi - Trieste, Istituto di Clinica Dermatologica
Background. It is known that standard oral formulation of cyclosporine A is a highly effective and safe treatment for moderate-severe psoriasis; however it shows an unpredictable intra- and inter-individual variability in bioavailability, due to many factors which may explain the variations in efficacy and tolerability and the isolated resistance to therapy. The new microemulsion formulation (Neoral) improves some of these problems for its better bioavailability and pharmacological stability.
Methods. In this study, the influence on the efficacy and tolerability of the switch from the conventional cyclosporine A to the new microemulsion formulation (Neoral) has been evaluated. Sixty-three out-patients affected with moderate-severe vulgar psoriasis (PASI: 10-30) have been studied.
Results. The efficacy of the new oral formulation (Neoral) was superior or equal to the traditional one in 95% of the patients; only in three cases (5%) the clinical picture worsened shortly after the switch. Minor adverse events arised in a lower percentage and intensity in comparison with the classical formulation.
Conclusions. Our data show that microemulsion formulation of Cyclosporine A has an equal or superior efficacy than the traditional one while the tolerability is better.